Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

This trial compared weekly injections of efpeglenatide, an exendin-based glucagon-like peptide-1 receptor agonist, at a dose of 4 or 6 mg with placebo in participants with known type 2 diabetes and either a history of cardiovascular disease or current kidney disease plus at least one other cardiovas...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 385; no. 10; pp. 896 - 907
Main Authors Gerstein, Hertzel C, Sattar, Naveed, Rosenstock, Julio, Ramasundarahettige, Chinthanie, Pratley, Richard, Lopes, Renato D, Lam, Carolyn S.P, Khurmi, Nardev S, Heenan, Laura, Del Prato, Stefano, Dyal, Leanne, Branch, Kelley
Format Journal Article
LanguageEnglish
Published Boston Massachusetts Medical Society 02.09.2021
Subjects
Agonists
Angina pectoris
Cardiology
Cardiology General
Cardiovascular disease
Cardiovascular diseases
Cerebral infarction
Chronic Kidney Disease
Constipation
Creatinine
Diabetes
Diabetes mellitus (non-insulin dependent)
Diarrhea
Drug dosages
Endocrinology
Glomerular filtration rate
Glucagon
Glucagon-like peptide 1
Glucose
Heart failure
Hemoglobin
Hospitalization
Hypoglycemia
Kidney diseases
Myocardial infarction
Nausea
Nephrology
Placebos
Risk factors
Sodium-glucose cotransporter
Vomiting
Online AccessGet full text

Cover

More Information
Summary:This trial compared weekly injections of efpeglenatide, an exendin-based glucagon-like peptide-1 receptor agonist, at a dose of 4 or 6 mg with placebo in participants with known type 2 diabetes and either a history of cardiovascular disease or current kidney disease plus at least one other cardiovascular risk factor. The risk of cardiovascular events was lower with efpeglenatide.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-News-2
ObjectType-Feature-3
content type line 23
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2108269